Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes.

Secondary hyperparathyroidism (SHPT) is associated with increased bone turnover, risk of fractures, vascular calcifications, and cardiovascular and all-cause mortality. The classical treatment for SHPT includes active vitamin D compounds and phosphate binders. However, achieving the optimal laborato...

Full description

Bibliographic Details
Main Author: Pereira, Pereira, Luciano Luciano (author)
Other Authors: Meng, Meng, Catarina Catarina (author), Marques, Marques, Daniela Daniela (author)
Format: article
Language:eng
Published: 2018
Subjects:
calcimimetic agents
chronic kidney disease
cinacalcet
etelcalcetide
secondary hyperparathyroidism
Online Access:http://hdl.handle.net/10400.26/25086
Country:Portugal
Oai:oai:comum.rcaap.pt:10400.26/25086

Internet

http://hdl.handle.net/10400.26/25086

Similar Items